Farm Out. Horse Dewormer from any retail livestock supply, apple flavor, Ivermectin.
https://www.horse.com/Search.aspx?query=ivermectin
- - "samples treated with 5 μM ivermectin at 48 h, equating to a 99.98% reduction in"
"...Ivermectin binds to and destabilises the Impα/β1 heterodimer thereby preventing Impα/β1 from binding to the viral protein (bottom) and preventing it from entering the nucleus. This likely results in reduced inhibition of the antiviral responses, leading to a normal, more efficient antiviral response."
https://www.sciencedirect.com/science/article/pii/S0166354220302011
The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro
Author links open overlay panelLeonCaly1Julian D.Druce1Mike G.Catton1David A.Jans2Kylie M.Wagstaff2
https://doi.org/10.1016/j.antiviral.2020.104787
Get rights and content
Under a Creative Commons license
open access
Highlights
• Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.
• A single treatment able to effect ∼5000-fold reduction in virus at 48h in cell culture.
• Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing.
• Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines.
Abstract
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
-
Can We Get A YeeHawww
https://www.horse.com/Search.aspx?query=ivermectin
- - "samples treated with 5 μM ivermectin at 48 h, equating to a 99.98% reduction in"
"...Ivermectin binds to and destabilises the Impα/β1 heterodimer thereby preventing Impα/β1 from binding to the viral protein (bottom) and preventing it from entering the nucleus. This likely results in reduced inhibition of the antiviral responses, leading to a normal, more efficient antiviral response."
https://www.sciencedirect.com/science/article/pii/S0166354220302011
The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro
Author links open overlay panelLeonCaly1Julian D.Druce1Mike G.Catton1David A.Jans2Kylie M.Wagstaff2
https://doi.org/10.1016/j.antiviral.2020.104787
Get rights and content
Under a Creative Commons license
open access
Highlights
• Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.
• A single treatment able to effect ∼5000-fold reduction in virus at 48h in cell culture.
• Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing.
• Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines.
Abstract
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
-
Last edited: